| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3269934 | HPB | 2010 | 19 Pages |
Abstract
The treatment of neuroendocrine liver metastases still needs to be standardized. Management in centres of expertise should be strongly encouraged in order to enable a multidisciplinary approach and personalized treatment. Development of molecular prognostic factors to select treatment according to patient risk should be attempted.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Endocrinology, Diabetes and Metabolism
Authors
Andrea Frilling, Georgios C. Sotiropoulos, Jun Li, Oskar Kornasiewicz, Ursula Plöckinger,